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STUDY PROTOCOL Open Access
Chronic pain self-management support
with pain science education and exercise
(COMMENCE): study protocol for a randomized
controlled trial
Jordan Miller1*, Joy C. MacDermid1, David M. Walton2 and Julie Richardson1
Abstract
Background: Previous research suggests that self-management programs for people with chronic pain improve
knowledge and self-efficacy but result in negligible effects on function. This study will investigate the effectiveness
self-management support with pain science education and exercise on improving function for people with chronic
pain in comparison to a wait-list control. A secondary objective is to determine which variables help to predict
response to the intervention.
Methods/Design: This study will be an unblinded, randomized controlled trial with 110 participants comparing a
6-week program that includes self-management support, pain science education and exercise to a wait-list control.
The primary outcome will be function measured by the Short Musculoskeletal Function Assessment - Dysfunction
Index. Secondary outcomes will include pain intensity measured by a numeric pain rating scale, pain interference
measured by the eight-item PROMIS pain interference item-bank, how much patients are bothered by functional
problems measured by the Short Musculoskeletal Function Assessment - Bother Index, catastrophic thinking measured
by the Pain Catastrophizing Scale, fear of movement/re-injury measured by the 11-item Tampa Scale of Kinesiophobia,
sense of perceived injustice measured by the Injustice Experience Questionnaire, self-efficacy measured by the Pain
Self-Efficacy Questionnaire, pain sensitivity measured by pressure pain threshold and cold sensitivity testing, fatigue
measured by a numeric fatigue rating scale, pain neurophysiology knowledge measured by the Neurophysiology of
Pain Questionnaire, healthcare utilization measured by number of visits to a healthcare provider, and work status.
Assessments will be completed at baseline, 7 and 18 weeks. After the 18-week assessment, the groups will crossover;
however, we anticipate carry-over effects with the treatment. Therefore, data from after the crossover will be used to
estimate within-group changes and to determine predictors of response that are not for direct between-
group comparisons. Mixed effects modelling will be used to determine between-group differences for all
primary and secondary outcomes. A series of multiple regression models will be used to determine predictors
of treatment response.
Discussion: This study has the potential to inform future self-management programming through evaluation
of a self-management program that aims to improve function as the primary outcome.
Trial registration: ClinicalTrials.gov NCT02422459, registered on 13 April 2015.
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Background
Approximately 19 to 29 % of Canadians, Americans and
Europeans experience chronic pain [1–3], and pain-
related disability is the largest contributor to years lived
with disability [4]. Pain related-disability has an import-
ant impact on the quality of life, workplace productivity
and the healthcare system [5–7]. It is important, there-
fore, to investigate strategies to improve quality of life
and reduce pain-related disability for people living with
chronic pain.
Self-management refers to an individual’s “ability to
manage the symptoms, treatment, physical and psy-
chosocial consequences and life style changes inherent
in living with a chronic condition. Efficacious self-
management encompasses ability to monitor one’s
condition and to effect the cognitive, behavioural and
emotional responses necessary to maintain a satisfac-
tory quality of life.” [8] Self-management support
aims to increase participants’ skills and confidence in
managing their health through the provision of educa-
tion and supportive interventions.
Self-management programs commonly evaluated in
the literature have included education on a number of
self-management strategies and often an opportunity to
practice these skills: problem solving, communication
with health care providers, use of healthcare resources
including medication, general stretching, strengthening,
and aerobic exercise, goal setting, diaries, self-monitoring,
relaxation, symptom management strategies and cognitive
strategies to help cope with pain [9, 10]. Evidence on the
effectiveness of self-management support for people ex-
periencing chronic pain is limited. Most research investi-
gating the impact of self-management support on pain
and disability include people with either arthritis or low
back pain [9]. The evidence suggests self-management
support improves knowledge and self-efficacy, but does
not produce clinically important effects on pain or func-
tion [9–11]. It is not clear whether these results generalize
to more diverse populations of people with chronic pain.
Two treatment approaches for people with chronic
pain that have not been included in traditional self-
management programs and demonstrate improvements
in function are pain neurophysiology education and indi-
vidualized, goal-oriented exercises. Pain neurophysiology
education has been defined as an educational interven-
tion and is useful for “describing the neurobiology and
neurophysiology of pain, and pain processing by the
nervous system” [12]. Pain neurophysiology education
is effective for individuals with chronic low back pain
[12–14], whiplash-associated disorder [15] and chronic
fatigue syndrome [16]. The influence of pain neuro-
physiology education on pain and function in other
chronic pain conditions has yet to be investigated with
a rigorous trial. Similarly, while most self-management
programs encourage participation in exercise and phys-
ical activity; most have not included individualized ex-
ercise programs despite evidence of reduced disability
for both musculoskeletal and neuropathic pain condi-
tions with these approaches [17–21]. The intervention
evaluated in this study will be self-management support
that incorporates individualized exercises and pain
neurophysiology education with a primary aim of im-
proving function.
It is also not clear from previous research which per-
sons are most likely to respond to chronic pain self-
management support. Previous research has suggested a
number of factors that may contribute to chronic pain
and reduced functional rehabilitation outcomes. For ex-
ample, high initial pain levels [22–24], female sex [23],
lower expectations of recovery [25], low pressure pain
thresholds [26], cold hyperalgesia [27–29], catastrophic
thinking [30–32], sense of perceived injustice [33] and
fear of movement or re-injury [34–36] have all been asso-
ciated with chronic pain, disability, or poor rehabilitation
outcomes. Some of these variables have been suggested as
prognostic indicators with more consistency than others.
This study will investigate whether some of these prognos-
tic indicators help predict response to chronic pain self-




1. This study will test the hypothesis that participants
with chronic pain experience greater improvement
in function over 18 weeks with 6 weeks of Chronic
Pain Self-management Support with Pain Science
Education and Exercise (COMMENCE) in comparison
to a wait-list control.
Secondary objectives
1. This study will test the hypotheses that people with
chronic pain experience greater pain intensity, pain
interference, self-efficacy, catastrophic thinking, fear
of movement/re-injury, pain neurophysiology
knowledge, bother by difficulty with functional
activities, fatigue, depressive symptoms, healthcare
utilization and work status with COMMENCE in
comparison to a wait-list control after 18 weeks.
2. This study will compare the change in outcomes
demonstrated by the wait-list group during their
treatment period (18 to 36 weeks) to the change
demonstrated during the wait-list period (0 to
18 weeks).
3. This study will estimate whether the impact of the
intervention is maintained over an intermediate
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follow-up term (18 to 36 weeks) in the treatment
group.
4. This study will determine whether the estimate of
the magnitude of the effect is influenced by an 18-
week delay.
5. This study will identify demographic, psychological




This study is a randomized trial with two parallel groups.
Participants will be allocated in a 1:1 ratio to treatment
and wait-list groups. After the 18-week assessment (after
the 6-week treatment period and the 12-week follow-up),
the group initially receiving COMMENCE will receive no
treatment, and the group initially on the wait-list will re-
ceive COMMENCE for 6 weeks. Both will be assessed
again at 25 and 36 weeks from the baseline (1 and
12 weeks after the wait-list group finishes treatment) (See
Fig. 1 for study flow). During the treatment, wait-list or
follow-up periods, participants can continue with usual
care with their family physician.
Between-group comparisons (objectives 1 and 2)
will be limited to the 0- to 18-week period prior to
the wait-list group receiving treatment. However, an
18- to 36-week period was added for ethical reasons
(that is, the wait-list group will receive the treatment)
and to allow four additional analyses to address ob-
jectives 3 to 6.
Blinding
Due to the nature of the treatment and comparison, par-
ticipants and the treating physiotherapist will not be
blinded to group allocation. The assessor who is com-
pleting the two objective measures will be blind to the
treatment allocation at all assessment time points. The
investigator performing the analysis will be blinded to
the treatment allocation.
Participants and setting
For the purposes of this study, 110 participants with
chronic pain will be recruited at Woodstock and Area
Community Health Centre (WACHC) in Woodstock,
Ontario, Canada. All participants will be referred to the
program by a healthcare provider at WACHC. WACHC
Fig. 1 Study flow diagram
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has an interdisciplinary team of healthcare providers that
work collaboratively to provide primary care, health pro-
motion and community development programs to prior-
ity populations in Oxford County, Ontario, Canada.
Since participants will be referred from WACHC, they
will meet at least one of the criteria for WACHC’s prior-
ity populations: addictions concerns, mental health chal-
lenges, low incomes, lack of health insurance, or isolated
seniors. Therefore, this sample will include people often
excluded from research and treatment by barriers to
accessing healthcare.
Included participants will all have been experiencing
noncancer related chronic pain. Chronic pain will be de-
fined as occurring in anyone who has been experiencing
pain for greater than 12 weeks. The pain can fluctuate in
intensity, but the patient must report experiencing pain
on a daily basis over the 3-month period. The presenta-
tion can be that of musculoskeletal pain or neuropathic
pain and can be associated with a traumatic (for example,
injury or surgery) or nontraumatic etiology (for example,
degenerative changes or pain of unknown etiology). Exclu-
sion criteria will include cancer related pain, medical “red
flags” suggestive of a non-neuromusculoskeletal etiology
of symptoms, casted fracture or surgery within the last
26 weeks and evidence of upper motor neuron lesion.
“Red flags” could include unremitting night pain,
palpable tumor, sudden weight loss or weight gain,
bowel or bladder incontinence, saddle anaesthesia, bi-
lateral or multisegmental loss of sensory or motor
function, fever/chills, diplopia, dysphagia, dysarthria,
drop attacks, or nystagmus.
Sample size
The sample size necessary for a randomized controlled
trial with three repeated measures at 0, 7 and 18 weeks
was calculated using online sample size software
(GLIMMPSE 2.0) using methods detailed by Muller et
al. [37–39]. The calculation was performed using a sig-
nificance level of 0.05, a power of 0.8, a minimum de-
tectable mean difference between groups of 10 points
on the Short Musculoskeletal Function Assessment
Dysfunction Index (SMFA-DI) [40] at both 7 weeks
and 18 weeks, and a standard deviation at each time-
point of 23 points on the SMFA-DI based on baseline
data from a series of 20 people with chronic pain re-
ferred to physiotherapy at WACHC. The calculations
were made assuming a correlation between baseline
and 7 weeks of 0.84, a correlation between baseline and
12 weeks of 0.82, and a correlation between 7 weeks
and 18 weeks of 0.84, based on the same clinical popu-
lation. The needed sample size calculated was 88 par-
ticipants. To account for a potential 20 % drop-out
rate, the investigators will recruit 110 participants (n =
55 in each group).
Allocation
The allocation sequence will be generated by a study
investigator (JMD) who is not involved in the enroll-
ment of participants or assigning interventions. A
computer-generated blocked random number schedule
will be used to determine allocation sequence. The
block size will be unknown to the other study investi-
gators. Participants will only be assessed and random-
ized if agreeable to participating in the group that
starts one week after the assessment. If participants
are unavailable for the upcoming group, both the
assessment and randomization will be deferred. The
allocation sequence will be concealed through the use
of sequentially numbered, opaque envelopes, which
will be opened by the physiotherapist (JM) and com-
municated to the patient after the initial assessment
is completed.
Enrollment
Patients will be screened and enrolled by the single
treating physiotherapist (JM) after receiving a referral
from a healthcare provider on the WACHC interdiscip-
linary team. The healthcare providers at WACHC will
be instructed to refer anyone with noncancer related pain
for at least 3 months. The physiotherapist will then screen
to determine whether the participant meets the inclusion
or exclusion criteria for participation in the trial.
Intervention/treatment
COMMENCE consists of two visits with a physio-
therapist per week over 6 weeks. One of the two
visits is in a group setting, where the emphasis is on
pain science education and self-management strat-
egies using cognitive behavioral principles to support
behavior change. The second visit is an individual-
ized, one-to-one session focused on providing sup-
port to implement self-management strategies and
develop an individualized, goal-oriented exercise pro-
gram. Both the individual sessions and the group ses-
sions will be carried out by a single physiotherapist
(JM) for all participants.
Group pain neurophysiology and self-management
education
The group sessions will include two to six people. The
reason for a maximum of six people is pragmatic due to
the maximum number of individual appointments the
physiotherapist can accommodate in his schedule at the
community health centre. The treatment group will
proceed with as few as two people in case of low recruit-
ment or high drop-out rate. The group sessions will be
interactive 1.5 hour sessions once per week over
6 weeks. The participant will be educated on science of
pain [12, 41] including the function of the nervous
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system, other systems involved in the pain experience,
changes in these systems when pain persists, neuroplas-
ticity, and self-management strategies to apply the in-
formation learned with the goal of increasing physical
activity and participation in life role activities while
controlling symptoms. The self-management strategies
included in this study are informed by evidence as well
as self-efficacy theory and social cognitive theory
[42–45]. Self-management strategies will include pro-
gressive goal setting [46–48], activity scheduling [49, 50],
thought monitoring [51], relaxation [52], sleep education
[53], reflection [51], self-monitoring [10], graded activity
[53–55] and exercise [19, 20]. The self-management
education has been designed with the priority popu-
lations in mind. Lower average income is one of the
priority populations, and this is associated with
lower levels of education and literacy [56]. The ma-
terial will be targeted toward those with less than a
high school education. Participants will be given a
workbook that guides them through the self-
management strategies including goal setting, activity
scheduling, using an activity and exercise log,
thought monitoring and graded activity planning. It
will be reviewed between the physiotherapist and
participant at each individual session to facilitate
communication, encourage discussion regarding an
individual implementation plan for each of the self-
management strategies discussed in the group, and
to provide an opportunity to review any material
covered in the group session.
Individualized self-management and exercise
The individualized sessions will be pragmatic 30 to
45 minute sessions once per week. The content will be
tailored to the individual and delivered by the same
physiotherapist (JM) who delivers the group sessions.
The individualized sessions will include developing an
implementation plan for the self-management strategies
discussed in the group session. Participants will also col-
laborate with the physiotherapist on a graded activity
plan to work towards functional goals and individual ex-
ercises to improve functional abilities to facilitate achiev-
ing functional goals. There will be three types of
exercises encouraged. The first (i) is frequent pain-free
movement, four to six times per day, six to ten repeti-
tions at a time. Participants collaborate with the physio-
therapist to find simple movements that can be
performed easily throughout their daily routines. The
purpose of these exercises is to reduce sensitivity to
movement and build confidence with movement that
does not increase pain. The second (ii) are exercises that
simulate functional tasks needed to perform goals, one
to two times per day at an intensity that allows the indi-
vidual to perform eight to 15 repetitions at a time. The
purpose of these exercises is to increase functional
abilities needed to resume participation in life-role ac-
tivities and participation goals set by the participant.
Education regarding progression will be provided fre-
quently throughout the program. The third (iii) is
regular aerobic exercise. Participants will choose any
aerobic activity they would like to participate in, set a
baseline volume and intensity for that activity and
create a plan with the physiotherapist for progression
over time. The volume and intensity will be deter-
mined using recommendations that participants do
not need to avoid pain at the time of exercise, but
should choose an intensity that does not result in
pain 1 to 2 hours after exercise. All three types of ex-
ercise will be delivered with messaging consistent
with self-management education that suggests exercise
is an effective way to manage pain and to prepare for
increases in participation in physical activity and life-
role activities.
Co-intervention
Participants will be free to continue with other treat-
ments. Other treatments will be recorded through self-
report at each assessment time-point and analyzed for
between-group differences.
Wait-list control
The wait-list control will be waiting to participate in
COMMENCE after the 18-week assessment, and partici-
pants will be free to continue with “usual care.” This in-
cludes continued use of prescribed medications and
recommendations from other healthcare providers. The
wait-list comparison was chosen rather than a more ro-
bust comparator due to previous evidence, suggesting no
difference in function when comparing other self-
management programs to no-treatment or usual-care
control groups.
Withdrawing participants from this study
Participants may withdraw from the treatment at any
time. Participants who choose to withdraw will be docu-
mented, and data will be analyzed as a member of the
group to which they were randomly assigned.
Ethical clearance
All participants will provide voluntary written informed
consent after a discussion about what study participa-
tion entails and the potential benefits and risks. In-
formed consent will be obtained by the treating
physiotherapist (JM) prior to the initial assessment
after receiving a referral from a health care provider for
each potential participant. Ethics approval has been ob-
tained from Hamilton Integrated Research Ethics Board
(HIREB #13-472).
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Outcomes
Self-report measures
All self-report measures have been demonstrated to be
reliable and valid in a population of people with persist-
ent pain. The ranges of each scale, as well as the min-
imal change considered clinically meaningful for this
study, are described in Table 1.
The primary outcome will be function as measured
by the Short-Musculoskeletal Function Assessment -
Dysfunction Index (SMFA-DI) [40].
Secondary outcomes will include the following:
1. Short Musculoskeletal Function Assessment -
Bother Index (SMFA-BI) [40]
2. Numeric Pain Rating Scale (NPRS) [57]
3. Numeric Fatigue Rating Scale (NFRS) [58]
4. PROMIS Pain Interference Item Bank - 8 items [59]
5. Patient Health Questionnaire (PHQ-9) [60–62]
6. Pain Catastrophizing Scale (PCS) [30, 63, 64]
7. Tampa Scale of Kinesiophobia - 11 (TSK-11) [65]
8. Pain Self Efficacy Questionnaire (PSEQ) [66–68]
9. Neurophysiology of Pain Questionnaire (NPQ) [69]
10.number of health care visits
11.work status
Potential predictors of response will include baseline
measures for each of the outcome measures listed above
as well as:
1. Post-traumatic Stress Disorder Checklist (PTSD-C)
[70, 71]
2. Injustice Experience Questionnaire (IEQ) [33]
3. number of medications [72]
4. disease count [72]
Demographic information
The following information will be collected at the ini-
tial assessment and analyzed as potential covariates
and predictors of response: age, sex, work status prior
Table 1 Outcome measures and potential predictors of response





Function Short Musculoskeletal Function Assessment - Dysfunction Index (SMFA-DI) 34–170 10 pointsa
How much participants are bothered by
difficulty with functional activities
Short Musculoskeletal Function Assessment - Bother Index
(SMFA-BI)
12–60 5.5 pointsa
Pain intensity Numeric Pain Rating Scale (NPRS) 0–10 2 points [86]
Fatigue Numeric Fatigue Rating Scale (NFRS) 0–10 1.4 points [87]
Pain interference PROMIS Pain Interference Item Bank - 8 items 8–40 5 pointsa
Depressive symptoms Patient Health Questionnaire - 9 (PHQ-9) 0–27 5 points [88]
Catastrophic thinking Pain Catastrophizing Scale (PCS) 0–52 38 % of scale [89]
Fear of symptom exacerbation 11-item Tampa Scale of Kinesiophobia (TSK-11) 11–44 5.6 points [90]
Pain neurophysiology knowledge Neurophysiology of pain test (NPT) 0–13 1.1 pointsa
Self efficacy Pain Self Efficacy Questionnaire (PSEQ) 0–60 11 points [91]
Work status Working versus not-working
Working full hours versus modified hours
Working full duties versus previous duties
Healthcare utilization # of health care visits during 12 weeks prior to treatment versus health
care visits during 12-week follow-up period
Post-traumatic stress symptoms Post-traumatic Stress Disorder Checklist 17–85
Sense of perceived injustice Injustice Experience Questionnaire (IEQ) 0–48
Medication use Number of medications
Medication by class
Comorbidities Disease count
Cold sensitivity A novel test of cold sensitivity
Pressure sensitivity Pressure Pain Threshold (PPT)
Legend: This table depicts each construct being measured as either an outcome or potential predictor of response, the measure used to evaluate that construct,
the range of the scale (if applicable), and the minimal important difference for scales that will be measured as outcomes
aIn the absence of an established MCID or MDC, change greater than half a standard deviation will be considered clinically meaningful [92]. In these instances,
clinical data from Woodstock and Area Community Health Centre was used to establish the standard deviation
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to symptom onset, length of time since symptom on-
set in months, diagnosis provided by a medical pro-
fessional as reported by the patient, medication use,
previous treatment received and expectations for re-
covery. Expectations for recovery will be assessed with
two questions: i) Do you think your pain will im-
prove? and ii) Do you think your functional abilities
will improve?
Psychophysical measures
Two psychophysical measures will be performed in
order to estimate sensitivity of the nervous system both
locally (at the point identified as “most tender”) and at
two standardized locations (the area of skin over the
muscle belly of the upper fibers of the trapezius and tibi-
alis anterior).
Pressure pain threshold
Pressure pain threshold will be measured using a hand-
held digital algometer (The Wagner FDX-25; Wagner
Instruments, Greenwich, CT), which has been previously
demonstrated to be reliable [26, 73]. The algometers will
be calibrated using a known-weight technique prior to
commencing the study. The algometer will be pressed
perpendicularly into the skin at a rate of approximately
50 kPa/s (5 N/s). The tester will be trained to ensure
ability to apply pressure consistently at this rate. Three
measurements of the pressure pain threshold will be re-
corded for each site and on each side of the body. The
pressure pain threshold will be determined using the fol-
lowing standardized instructions, used in a previous
study investigating pressure pain threshold [74]: “I’m go-
ing to begin applying pressure to your skin. I want you
to tell me the moment the sensation changes from com-
fortable pressure to slightly unpleasant pain.” For consis-
tencym the more tender side will be tested first followed
by the less tender side at the “most tender” location. At
the standardized locations, the right side will be tested
first, followed by the left.
Cold hyperalgesia testing
Cold hyperalgesia will be tested using a novel test. This
device consists of a Peltier Cooler used to cool 2 pairs of
cylinders. The two pairs of cylinders are made of acrylic
and copper. When the temperature of the cooler is 0 de-
grees, the cylinders of different materials will feel similar
to different temperatures on the skin. The acrylic cylin-
der will feel like 18 degrees, and the copper will feel like
0 degrees. Each of the two cylinders will be placed in
contact with the skin at the three locations in the same
randomized order as was used for pressure pain thresh-
old. The order of the two materials will also be random-
ized with each of the two materials being placed on the
skin three times on each side. The participant will be
asked to rate how cold the cylinder is on a 21 point scale
(0 is unable to detect the temperature, 10 is cold but not
painful, 11 is cold and slightly uncomfortable, and 20 is
unbearable pain).
Adverse events or harms
Participants will be asked by the physiotherapist at each
visit about adverse events that the patient associates with
treatment. Any adverse events requiring medical care
beyond the scope of the treating physiotherapist will be
referred immediately.
Treatment adherence
Treatment adherence will be assessed through a com-
bination of attendance (categorized as < 25 %, 25 to
49 %, 50 to 74 %, or ≥ 75 % of visits) and adherence to
self-management strategies. Adherence to recommended
self-management strategies will be described as either
completed or not completed by the clinician when
reviewing the participant workbook at the individual
treatment session.
Timeline for assessments
Assessments will take place at baseline, 7 weeks (1-week
follow-up), 18 weeks (12-week follow-up), 25 weeks (1-
week follow-up after wait-list group treatment period)
and 36 weeks (12-week follow-up after wait-list group
treatment period). See Fig. 1 for the flow diagram.
Demographic information will be collected at the base-
line assessment. Self-reported outcome measures will be
collected at all assessment time-points. The two object-
ive tests will be collected at baseline, 18 weeks and
36 weeks.
Participant retention
Participant retention will be encouraged by clearly ask-
ing only those willing to commit to all assessment and
treatment time points to enroll in the study. In addition,
free parking is provided for all treatment and assessment
visits, treatment is provided free-of-charge, and a small
gift card ($20) is provided at each assessment time point
to thank participants and encourage patient follow-up.
Data collection and management
Hard copies of self-report data will be collected directly
for the outcome measures previously listed and refer-
enced. The measures will be completed at WACHC,
with the treating physiotherapist and a research assistant
present. Demographic data will be collected on pre-
piloted study forms. Data will be transferred directly to a
database by a trained research assistant or study investi-
gator. Data quality will be assured through checking
10 % of the data entered. The data will be collected and
stored using only participant codes with no patient
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identifiers. Hard copies of forms will be stored in a
locked cabinet within a locked office at WACHC. The
electronic database will be password protected and
stored on a password protected computer. Only study
investigators or staff will have access to the data.
Data monitoring and auditing
This trial will not have a data monitoring committee and
will not include auditing of the study conduct outside of
the study investigators. This decision was made because
of an estimated low risk to participants. Participants
with chronic pain will be medically stable and are not
expected to be at a high risk of mortality. In addition,
self-management programs, exercise, and pain education
have all been studied with no serious adverse events re-
ported, so no harm to patients is expected with this
intervention. There are no stop rules or preliminary ana-
lyses planned.
Analysis
Statistical analysis will be conducted using Stata soft-
ware, version 13 (StataCorp, College Station, TX, USA).
Baseline characteristics for both treatment and wait-list
groups will be presented as means and standard devia-
tions for normal data, and medians and interquartile
range for non-normal data, and number of patients and
percentages for categorical data. Between-group compar-
isons will be made for baseline data using a Student’s t-
test for continuous data and Chi squared or Fisher’s
exact test for categorical variables to determine the re-
sults of the randomized allocation.
To address objectives #1 and 2, between-group differ-
ences in change in primary (SMFA-DI) and secondary
outcomes will be analyzed using linear mixed-effects
modelling with repeated measures at 0, 7, and 18 weeks.
A P value of less than 0.05 will be considered indicative
of statistical significance for all comparisons. The mini-
mum changes required for the change to be considered
clinically meaningful for each scale are listed in
Table 1. An advantage of using linear mixed-effects
modelling is the ability to utilize all available data
points without multiple imputation when there are
multiple missing data points [75]. Between-group
comparisons will be limited to data collected before
the 18-week assessment time point due to anticipated
carry over effects due to the long-term changes in
function associated with exercise approaches for
people with chronic pain [19, 20]. Analysis will use
intention-to-treat principles.
To address objective #3, a within-group analysis in the
wait-list group will be performed comparing the change
in function during the treatment period (weeks 18 to 36)
to the change in function during the wait-list period
(weeks 0 to 18) using a mixed effects model. If there is
no change during the wait-list period, this analysis allows
for a secondary estimate of treatment effect similar to a
diamond response design [76]. Goldsmith et al. suggest
that if the magnitude of the effect of the intervention is
similar to that estimated through the comparison be-
tween groups during the 0 to 7 week period, then they
may be pooled for a more precise estimate of treatment
effect [76].
To address objective #4 and estimate whether treat-
ment effects are maintained beyond the 18-week assess-
ment, the functional score (SMFA-DI) at the end of
treatment (7 weeks) will be compared with the func-
tional score at the 25- and 36-week assessments using a
linear mixed effects model.
To address objective #5, the influence of the 18-week
delay on the treatment effect will be determined by com-
paring the magnitude of treatment effect from the waist
list group (from objective #3) with the estimate of the
magnitude of treatment effect from the treatment group
(from objective #1).
In order to address objective #6, each of the patient
demographics, outcome measure scores, and objective
measures will be tested for univariate relationship with
SMFA-DI change score at 18 weeks (difference between
SMFA-DI at 18 weeks and SMFA-DI at baseline) using a
Pearson r for continuous variables and Chi squared
tests for categorical variables. Variables with a signifi-
cance of <0.10 will be included in the multivariate ana-
lysis so that no potential predictive variables will be
overlooked. Potential predictor variables will be entered
into a series of multiple regression models to determine
which combination of baseline variables best predict
changes in SMFA-DI.
Sensitivity analyses
There will be two planned sensitivity analyses. The
first sensitivity analysis will compare participants who
attend at least 75 % (9/12) of treatment visits to the
wait-list control group to gain an estimate of efficacy
versus effectiveness. If there are any cases removed
from analysis due to a high influence on the mixed
effects model (cooks distance > 4/n) [77], a sensitivity
analysis will also be performed to compare the results
of the mixed effects model with and without highly in-
fluential points included.
Protocol modifications
Any changes to protocol will be communicated with
all study investigators and the Hamilton Research
Ethics Board in writing. If there are any changes, the
trial registry (clinicaltrials.gov) will be updated elec-
tronically. If the risks to participants change, all trial
participants will be contacted directly by phone to
communicate the change.
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Discussion
A number of limitations in this protocol may contribute
to a risk of bias. First, due to the nature of the interven-
tion and comparison, the participants and the healthcare
provider cannot be blinded. The primary outcome is a
self-report measure completed by the participants (not
blinded) and secondary outcomes are either self-report
measures (not blinded) or psychophysical tests con-
ducted by research assistants (blinded). The principle in-
vestigator (JM) is also the treating physiotherapist and
will be present at the assessments. Additionally, the na-
ture of the comparison could influence the risk of bias.
Patients in the wait-list group will understand that they
are not receiving the intervention under investigation,
and this could bias their self-report assessments at 7 and
18 weeks.
Having a single therapist and center influences the
generalizability of the results. While easily generalizable
to the physiotherapist and setting in which the study
was carried out, the ability to generalize the results to
other settings and other settings is limited due to the po-
tential of a therapist effect. A limitation of the current
study design is that results may be attributed to either
the intervention or the therapist effect without the abil-
ity to distinguish between the two potential mechanisms.
Another important factor when considering the
generalizability of results is the population being studied.
The priority populations at WACHC include people
with addictions concerns, mental health challenges, low
incomes, lack of health insurance and isolated seniors.
This group experiences a number of barriers to acces-
sing healthcare, and therefore, it is possible that attend-
ance and adherence to the program will be low. Also,
people with multiple morbidities have a lower functional
status and experience greater functional decline with age
[78]. This may limit the potential for functional gains in
this population and may make it challenging to deter-
mine which factors are contributing to reduced function
in this population. These factors make generalizability to
a population experiencing similar barriers to accessing
healthcare easier; however, generalizability to other pop-
ulations without such barriers is more challenging.
The population of people with barriers to accessing
healthcare also poses a risk of higher attrition rates.
For example, people with depression, substance abuse
issues, and lower education are more likely to be lost
due to failure to locate [79, 80]. The investigators
have put in place measures to try to minimize the at-
trition rate, including asking for multiple methods of
contacting the participant and planning to make mul-
tiple attempts to contact the participant for follow-
up appointments.
Another limitation of this study design is the short-
term follow-up before the wait-list group receives
treatment. Estimating whether changes in function are
maintained in the longer term (up to 36 weeks) will rely
on within-group analysis of the treatment group. Given
the lack of comparison, these results should be inter-
preted with caution. Changes at 25- and 36-week follow-
up could be due to lasting treatment effects; however,
period effects could also contribute to any long-term
changes. Despite the limitations, the investigators con-
sidered it important to estimate the longer-term changes
in function to inform future research on long-term
efficacy.
Similarly, the comparison of the treatment period
(weeks 18 to 36) with the wait-list period (weeks 0 to
18) in the wait-list group should be interpreted with cau-
tion given the lack of comparison group. Between-group
comparisons performed during weeks 0 to 18 will pro-
vide a better estimate of treatment effect; however, the
secondary estimate of treatment effect can add precision
to effect estimates and allows investigators to estimate
the impact of an 18-week delay before starting the self-
management program. It is important that within-group
changes are not be compared between groups as this has
the potential to be misleading [81].
Treatment of chronic pain is a challenge [82, 83]. Im-
proving function is frequently reported as an important
outcome by people living with chronic pain [84], and re-
ducing pain-related disability is important for reducing
the financial burden [5–7]. Self-management represents
an important opportunity to improve pain-related dis-
ability and ultimately the impact of chronic pain [85].
Unfortunately, existing evidence suggests chronic pain
self-management support does not result in substantial
changes in participant function [9, 10]. This study aims
to evaluate a new approach to chronic pain self-
management that targets function as the primary out-
come. If this approach is demonstrates effectiveness, this
could inform self-management programming to include
greater focus on pain neurophysiology education and
physiotherapist-led, individualized, goal-oriented exer-
cise. By determining which factors help to predict an
intervention response, practitioners will have valuable
information on the prognosis of participants entering
the program. Future research may help to develop tai-
lored approaches to self-management for persons less
likely to respond to this approach. Ultimately, this re-
search could help to improve self-management for
people with chronic pain.
The results of this trial will be published in peer-
reviewed journals and presented at international confer-
ences in the fields of pain and rehabilitation.
Trial status
Recruitment started in September 2013. At the time of
protocol submission, this study is recruiting patients.
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Dissemination
This study will be published in a leading journal and
presented at international conferences in the field of
pain and rehabilitation. A lay summary of results will be
sent to study participants. Additionally, study results will
be disseminated to clinicians through courses, presenta-
tions and workshops to a community of practice of
physiotherapists in primary health care and a network of
physiotherapists interested in the treatment of pain.
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